MetMed Medical to attend the ECIO Congress in Dublin from the 17th to the 20th of April
The European Congress of Interventional Oncology brings together the leading specialists in Interventional Oncology, a branch of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using minimally invasive procedures performed under image guidance.
One of the innovative treatments introduced into the field of Interventional Oncology over the last five years is the Delcath Hepatic CHEMOSAT® Delivery System. The CHEMOSAT® device is used for percutaneous intra-arterial administration of chemotherapeutic agent (melphalan hydrochloride) to the liver with subsequent extracorporeal filtration of the regional (hepatic) venous blood, lowering the concentration of chemotherapeutic agent in the blood before returning it to the systemic venous circulation. The concept of chemosaturation is to temporarily isolate the liver from the body's blood circulation and deliver concentrated doses of an anti-cancer drug directly to the liver, “saturating" the entire organ.
CHEMOSAT® has shown positive results in patients with Ocular Melanoma, Cholangiocarcicoma, Neuroendocrine Tumours and other types of primary cancer with metastases in the liver. The treatment is available at leading cancer centres across Europe, including Hospital Sanchinarrio in Madrid and Clinica Rotger on Mallorca.
MetaMed Medical is commercial representative of Delcath Inc., the manufacturer of the Hepatic CHEMOSAT® Delivery System.
If you would like to learn more about the Hepatic CHEMOSAT® Delivery System, please contact us to arrange a meeting either at the conference in Dublin or your medical institution.
looking forward to improve
We are always happy to receive feedback. If you have any comments or suggestions let us know via the Contact Form under the Contact section.